SCHEMBL443768

SCHEMBL443768

CCCC1(C(O)c2ccc(Cl)c(Cl)c2)CCC(C)(C)N1C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.33
SLC6A2 P23975 5/20 0.33
SLC6A4 P31645 5/20 0.33
SLC6A3 Q01959 5/20 0.33
CYP2D6 P10635 3/20 0.33
KCNH2 Q12809 1/20 0.33
FFAR1 O14842 1/20 0.33
OPRK1 P41145 1/20 0.33
CCR5 P51681 2/20 0.32
KDM1A O60341 1/20 0.32
HSD17B2 P37059 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444129 0.84 KCNQ2 (0.36) KCNQ2SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL444534 0.82 SLC6A3 (0.37) KCNQ2SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL446410 0.81 KCNQ2 (0.39) KCNQ2SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL441894 0.77 KCNQ2 (0.36) KCNQ2SLC6A2SLC6A4SLC6A3OPRK1
SCHEMBL444255 0.76 SLC6A4 (0.45) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL443940 0.74 SLC6A3 (0.38) KCNQ2SLC6A2SLC6A4SLC6A3OPRK1
SCHEMBL443919 0.74 ERBB2 (0.33) OPRK1
SCHEMBL443325 0.74 ERBB2 (0.33) OPRK1
SCHEMBL443918 0.74 ERBB2 (0.33) OPRK1
SCHEMBL443917 0.74 ERBB2 (0.33) OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2684871-B1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives HOFFMANN LA ROCHE (CH) 2016-05-04 EP disclosed
EP-2684871-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives F. Hoffmann-La Roche AG (CH) 2014-01-15 EP disclosed
US-8513425-B2 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2013-08-20 US disclosed
US-20120065225-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF IYER PRAVIN (US) 2012-03-15 US disclosed
US-8084623-B2 heterocyclic ketones such as (3-Benzyl-pyrrolidin-3-yl)-(1H-indol-5-yl)-methanone, used as antidepressants or anxiolytic agents ROCHE PALO ALTO LLC (US) 2011-12-27 US disclosed
EP-2354124-A2 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives F. Hoffmann-La Roche AG (CH) 2011-08-10 EP disclosed
EP-2297096-A2 ARYL KETONE AS MRI F. Hoffmann-La Roche AG (CH) 2011-03-23 EP disclosed
US-20090318493-A1 Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2009-12-24 US disclosed
WO-2009153178-A2 ARYL KETONE AS MRI F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065225-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF CNKSR1, RB1, AR KCNQ2 642/4885SLC6A2 4870/4885SLC6A4 4855/4885
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof CNKSR1, RB1, AR KCNQ2 642/4885SLC6A2 4870/4885SLC6A4 4855/4885
US-20090318493-A1 Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof TPH2, TPH1, ADRA2C KCNQ2 205/4885SLC6A2 71/4885SLC6A4 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.